世界の重症筋無力症（MG）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myasthenia Gravis (MG) Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4538
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、108ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、重症筋無力症（MG）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、迅速免疫療法、その他）、用途別市場規模（病院・クリニック、診断センター、学術・研究機関）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・重症筋無力症（MG）治療の市場動向
・企業の競争状況、市場シェア
・重症筋無力症（MG）治療の種類別市場規模と予測2016-2027（薬物治療、迅速免疫療法、その他）
・重症筋無力症（MG）治療の用途別市場規模と予測2016-2027（病院・クリニック、診断センター、学術・研究機関）
・重症筋無力症（MG）治療の北米市場規模2016-2027（アメリカ、カナダ）
・重症筋無力症（MG）治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・重症筋無力症（MG）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・重症筋無力症（MG）治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・重症筋無力症（MG）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Alexion Pharmaceutical、Grifols、Avadel Pharmaceuticals、Novartis、Pfizer、AbbVie、F. Hoffmann-La Roche、GlaxoSmithKline、Bausch Health Companies、Shire）
・結論

Market Analysis and Insights: Global Myasthenia Gravis (MG) Treatment Market
The global Myasthenia Gravis (MG) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myasthenia Gravis (MG) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myasthenia Gravis (MG) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myasthenia Gravis (MG) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myasthenia Gravis (MG) Treatment market.

Global Myasthenia Gravis (MG) Treatment Scope and Market Size
Myasthenia Gravis (MG) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis (MG) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drug Treatment
Rapid Immunotherapies
Others

Segment by Application
Hospitals and Clinics
Diagnostic Centers
Academic and Research Organizations

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Alexion Pharmaceutical
Grifols
Avadel Pharmaceuticals
Novartis
Pfizer
AbbVie
F. Hoffmann-La Roche
GlaxoSmithKline
Bausch Health Companies
Shire

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myasthenia Gravis (MG) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Treatment
1.2.3 Rapid Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Myasthenia Gravis (MG) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Centers
1.3.4 Academic and Research Organizations
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myasthenia Gravis (MG) Treatment Market Perspective (2016-2027)
2.2 Myasthenia Gravis (MG) Treatment Growth Trends by Regions
2.2.1 Myasthenia Gravis (MG) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myasthenia Gravis (MG) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Myasthenia Gravis (MG) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Myasthenia Gravis (MG) Treatment Industry Dynamic
2.3.1 Myasthenia Gravis (MG) Treatment Market Trends
2.3.2 Myasthenia Gravis (MG) Treatment Market Drivers
2.3.3 Myasthenia Gravis (MG) Treatment Market Challenges
2.3.4 Myasthenia Gravis (MG) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis (MG) Treatment Players by Revenue
3.1.1 Global Top Myasthenia Gravis (MG) Treatment Players by Revenue (2016-2021)
3.1.2 Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Myasthenia Gravis (MG) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis (MG) Treatment Revenue
3.4 Global Myasthenia Gravis (MG) Treatment Market Concentration Ratio
3.4.1 Global Myasthenia Gravis (MG) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis (MG) Treatment Revenue in 2020
3.5 Myasthenia Gravis (MG) Treatment Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis (MG) Treatment Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis (MG) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myasthenia Gravis (MG) Treatment Breakdown Data by Type
4.1 Global Myasthenia Gravis (MG) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Myasthenia Gravis (MG) Treatment Forecasted Market Size by Type (2022-2027)

5 Myasthenia Gravis (MG) Treatment Breakdown Data by Application
5.1 Global Myasthenia Gravis (MG) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Myasthenia Gravis (MG) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myasthenia Gravis (MG) Treatment Market Size (2016-2027)
6.2 North America Myasthenia Gravis (MG) Treatment Market Size by Type
6.2.1 North America Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021)
6.2.2 North America Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027)
6.2.3 North America Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2027)
6.3 North America Myasthenia Gravis (MG) Treatment Market Size by Application
6.3.1 North America Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021)
6.3.2 North America Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027)
6.3.3 North America Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2027)
6.4 North America Myasthenia Gravis (MG) Treatment Market Size by Country
6.4.1 North America Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021)
6.4.2 North America Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Myasthenia Gravis (MG) Treatment Market Size (2016-2027)
7.2 Europe Myasthenia Gravis (MG) Treatment Market Size by Type
7.2.1 Europe Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2027)
7.3 Europe Myasthenia Gravis (MG) Treatment Market Size by Application
7.3.1 Europe Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2027)
7.4 Europe Myasthenia Gravis (MG) Treatment Market Size by Country
7.4.1 Europe Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Type
8.2.1 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Application
8.3.1 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Region
8.4.1 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myasthenia Gravis (MG) Treatment Market Size (2016-2027)
9.2 Latin America Myasthenia Gravis (MG) Treatment Market Size by Type
9.2.1 Latin America Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2027)
9.3 Latin America Myasthenia Gravis (MG) Treatment Market Size by Application
9.3.1 Latin America Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2027)
9.4 Latin America Myasthenia Gravis (MG) Treatment Market Size by Country
9.4.1 Latin America Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Type
10.2.1 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Application
10.3.1 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Country
10.4.1 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Alexion Pharmaceutical
11.1.1 Alexion Pharmaceutical Company Details
11.1.2 Alexion Pharmaceutical Business Overview
11.1.3 Alexion Pharmaceutical Myasthenia Gravis (MG) Treatment Introduction
11.1.4 Alexion Pharmaceutical Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.1.5 Alexion Pharmaceutical Recent Development
11.2 Grifols
11.2.1 Grifols Company Details
11.2.2 Grifols Business Overview
11.2.3 Grifols Myasthenia Gravis (MG) Treatment Introduction
11.2.4 Grifols Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.2.5 Grifols Recent Development
11.3 Avadel Pharmaceuticals
11.3.1 Avadel Pharmaceuticals Company Details
11.3.2 Avadel Pharmaceuticals Business Overview
11.3.3 Avadel Pharmaceuticals Myasthenia Gravis (MG) Treatment Introduction
11.3.4 Avadel Pharmaceuticals Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.3.5 Avadel Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Myasthenia Gravis (MG) Treatment Introduction
11.4.4 Novartis Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Myasthenia Gravis (MG) Treatment Introduction
11.5.4 Pfizer Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Myasthenia Gravis (MG) Treatment Introduction
11.6.4 AbbVie Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.6.5 AbbVie Recent Development
11.7 F. Hoffmann-La Roche
11.7.1 F. Hoffmann-La Roche Company Details
11.7.2 F. Hoffmann-La Roche Business Overview
11.7.3 F. Hoffmann-La Roche Myasthenia Gravis (MG) Treatment Introduction
11.7.4 F. Hoffmann-La Roche Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.7.5 F. Hoffmann-La Roche Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Myasthenia Gravis (MG) Treatment Introduction
11.8.4 GlaxoSmithKline Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.8.5 GlaxoSmithKline Recent Development
11.9 Bausch Health Companies
11.9.1 Bausch Health Companies Company Details
11.9.2 Bausch Health Companies Business Overview
11.9.3 Bausch Health Companies Myasthenia Gravis (MG) Treatment Introduction
11.9.4 Bausch Health Companies Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.9.5 Bausch Health Companies Recent Development
11.10 Shire
11.10.1 Shire Company Details
11.10.2 Shire Business Overview
11.10.3 Shire Myasthenia Gravis (MG) Treatment Introduction
11.10.4 Shire Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021)
11.10.5 Shire Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myasthenia Gravis (MG) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Treatment
Table 3. Key Players of Rapid Immunotherapies
Table 4. Key Players of Others
Table 5. Global Myasthenia Gravis (MG) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Myasthenia Gravis (MG) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myasthenia Gravis (MG) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Myasthenia Gravis (MG) Treatment Market Share by Regions (2016-2021)
Table 9. Global Myasthenia Gravis (MG) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Myasthenia Gravis (MG) Treatment Market Share by Regions (2022-2027)
Table 11. Myasthenia Gravis (MG) Treatment Market Trends
Table 12. Myasthenia Gravis (MG) Treatment Market Drivers
Table 13. Myasthenia Gravis (MG) Treatment Market Challenges
Table 14. Myasthenia Gravis (MG) Treatment Market Restraints
Table 15. Global Myasthenia Gravis (MG) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Myasthenia Gravis (MG) Treatment Market Share by Players (2016-2021)
Table 17. Global Top Myasthenia Gravis (MG) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis (MG) Treatment as of 2020)
Table 18. Ranking of Global Top Myasthenia Gravis (MG) Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Myasthenia Gravis (MG) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Myasthenia Gravis (MG) Treatment Product Solution and Service
Table 22. Date of Enter into Myasthenia Gravis (MG) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Myasthenia Gravis (MG) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Myasthenia Gravis (MG) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Myasthenia Gravis (MG) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Alexion Pharmaceutical Company Details
Table 63. Alexion Pharmaceutical Business Overview
Table 64. Alexion Pharmaceutical Myasthenia Gravis (MG) Treatment Product
Table 65. Alexion Pharmaceutical Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 66. Alexion Pharmaceutical Recent Development
Table 67. Grifols Company Details
Table 68. Grifols Business Overview
Table 69. Grifols Myasthenia Gravis (MG) Treatment Product
Table 70. Grifols Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 71. Grifols Recent Development
Table 72. Avadel Pharmaceuticals Company Details
Table 73. Avadel Pharmaceuticals Business Overview
Table 74. Avadel Pharmaceuticals Myasthenia Gravis (MG) Treatment Product
Table 75. Avadel Pharmaceuticals Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 76. Avadel Pharmaceuticals Recent Development
Table 77. Novartis Company Details
Table 78. Novartis Business Overview
Table 79. Novartis Myasthenia Gravis (MG) Treatment Product
Table 80. Novartis Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 81. Novartis Recent Development
Table 82. Pfizer Company Details
Table 83. Pfizer Business Overview
Table 84. Pfizer Myasthenia Gravis (MG) Treatment Product
Table 85. Pfizer Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 86. Pfizer Recent Development
Table 87. AbbVie Company Details
Table 88. AbbVie Business Overview
Table 89. AbbVie Myasthenia Gravis (MG) Treatment Product
Table 90. AbbVie Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 91. AbbVie Recent Development
Table 92. F. Hoffmann-La Roche Company Details
Table 93. F. Hoffmann-La Roche Business Overview
Table 94. F. Hoffmann-La Roche Myasthenia Gravis (MG) Treatment Product
Table 95. F. Hoffmann-La Roche Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 96. F. Hoffmann-La Roche Recent Development
Table 97. GlaxoSmithKline Company Details
Table 98. GlaxoSmithKline Business Overview
Table 99. GlaxoSmithKline Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 100. GlaxoSmithKline Recent Development
Table 101. Bausch Health Companies Company Details
Table 102. Bausch Health Companies Business Overview
Table 103. Bausch Health Companies Myasthenia Gravis (MG) Treatment Product
Table 104. Bausch Health Companies Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 105. Bausch Health Companies Recent Development
Table 106. Shire Company Details
Table 107. Shire Business Overview
Table 108. Shire Myasthenia Gravis (MG) Treatment Product
Table 109. Shire Revenue in Myasthenia Gravis (MG) Treatment Business (2016-2021) & (US$ Million)
Table 110. Shire Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis (MG) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drug Treatment Features
Figure 3. Rapid Immunotherapies Features
Figure 4. Others Features
Figure 5. Global Myasthenia Gravis (MG) Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospitals and Clinics Case Studies
Figure 7. Diagnostic Centers Case Studies
Figure 8. Academic and Research Organizations Case Studies
Figure 9. Myasthenia Gravis (MG) Treatment Report Years Considered
Figure 10. Global Myasthenia Gravis (MG) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Myasthenia Gravis (MG) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Myasthenia Gravis (MG) Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Myasthenia Gravis (MG) Treatment Market Share by Regions (2022-2027)
Figure 14. Global Myasthenia Gravis (MG) Treatment Market Share by Players in 2020
Figure 15. Global Top Myasthenia Gravis (MG) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis (MG) Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Myasthenia Gravis (MG) Treatment Revenue in 2020
Figure 17. Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Myasthenia Gravis (MG) Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Myasthenia Gravis (MG) Treatment Market Share by Type (2016-2027)
Figure 21. North America Myasthenia Gravis (MG) Treatment Market Share by Application (2016-2027)
Figure 22. North America Myasthenia Gravis (MG) Treatment Market Share by Country (2016-2027)
Figure 23. United States Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myasthenia Gravis (MG) Treatment Market Share by Type (2016-2027)
Figure 27. Europe Myasthenia Gravis (MG) Treatment Market Share by Application (2016-2027)
Figure 28. Europe Myasthenia Gravis (MG) Treatment Market Share by Country (2016-2027)
Figure 29. Germany Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Myasthenia Gravis (MG) Treatment Market Share by Region (2016-2027)
Figure 39. China Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myasthenia Gravis (MG) Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Myasthenia Gravis (MG) Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Myasthenia Gravis (MG) Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Myasthenia Gravis (MG) Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Myasthenia Gravis (MG) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Alexion Pharmaceutical Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 59. Grifols Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 60. Avadel Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 61. Novartis Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 63. AbbVie Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 64. F. Hoffmann-La Roche Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 66. Bausch Health Companies Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 67. Shire Revenue Growth Rate in Myasthenia Gravis (MG) Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Global Microscopic Polyangiitis(MPA) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4506 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、顕微鏡的多発血管炎（MPA）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アバコパン、免疫グロブリン、リツキシマブバイオシミラー、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別...

世界の結核（TB）治療市場規模・現状・予測（2021年-2027年）

Global Tuberculosis (TB) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4987 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、結核（TB）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（イソニアジド、リファンピン（リファディン、リマクタン）、エタンブトール（ミアンブトール）、ピラジナミド）、用途別市場規模（活動性結核、潜...

世界の尿素サイクル異常症（UCD）治療市場規模・現状・予測（2021年-2027年）

Global Urea Cycle Disorders (UCD) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5000 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、尿素サイクル異常症（UCD）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アミノ酸式、フェニル酪酸、安息香酸ナトリウム、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別...

世界の原始神経外胚葉性腫瘍（PNET）治療市場規模・現状・予測（2021年-2027年）

Global Primitive Neuroectodermal Tumors (PNET) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4766 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、原始神経外胚葉性腫瘍（PNET）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（外科手術、化学療法、放射線療法）、用途別市場規模（病院、外来手術センター、その他）、主要地域別市場規模（北米、アメリ...

世界の慢性難治性咳（CRC）治療市場規模・現状・予測（2021年-2027年）

Global Chronic Refractory Cough (CRC) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5661 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、慢性難治性咳（CRC）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（言語療法、理学療法）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓...

世界の骨髄性プロトポルフィリン症（EPP）治療市場規模・現状・予測（2021年-2027年）

Global Erythropoietic Protoporphyria (EPP) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4205 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、骨髄性プロトポルフィリン症（EPP）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ホルモン療法、補助療法、光線療法）、用途別市場規模（病院薬局、ドラッグストア、小売薬局、オンライン薬局）、主要地...

世界のB細胞非ホジキンリンパ腫（NHL）治療市場規模・現状・予測（2021年-2027年）

Global B-Cell Non-Hodgkin's Lymphoma (NHL) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3894 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、B細胞非ホジキンリンパ腫（NHL）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、放射線療法、その他）、用途別市場規模（病院、診療所、外来手術センター、その他）、主要地域別市場規模（北米...

世界の乳腺線維嚢胞診断＆治療市場規模・現状・予測（2021年-2027年）

Global Fibrocystic Breasts Diagnostics and Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4225 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、乳腺線維嚢胞診断＆治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（診断、治療）、用途別市場規模（病院、診療所、診断センター、研究所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本...

世界の慢性リンパ性白血病（CLL）治療市場規模・現状・予測（2021年-2027年）

Global Chronic Lymphocytic Leukemia (CLL) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4011 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、慢性リンパ性白血病（CLL）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（CLL初期治療、CLL二次治療）、用途別市場規模（大人用、子供用）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日...

世界の顧みられない熱帯病（NTD）治療市場規模・現状・予測（2021年-2027年）

Global Neglected Tropical Disease (NTD) Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4558 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、顧みられない熱帯病（NTD）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、ワクチン）、用途別市場規模（病院・クリニック、診断センター、学術・研究機関）、主要地域別市場規模（北米、アメリカ...

世界の非薬物式うつ病治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Drug Free Depression Treatment Market The global Drug Free Depression Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data int…
世界の顧みられない熱帯病（NTD）治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Neglected Tropical Disease (NTD) Treatment Market The global Neglected Tropical Disease (NTD) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in an…
世界の乳腺線維嚢胞診断＆治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Fibrocystic Breasts Diagnostics and Treatment Market The global Fibrocystic Breasts Diagnostics and Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy…
世界のスポロトリクスシェンキー感染症治療市場規模・現状・予測（2021年-2027年） Skin-related issues are one of the frequently occurring issues worldwide. One such issue is Sporotrichosis. Sporotrichosis is caused by a dimorphic fungus, called Sporothrix Schenckii, and is commonly called gardeners' disease due to number of people affected when carrying out cultivation in farms a…
世界の色汗症治療市場規模・現状・予測（2021年-2027年） Chromhidrosis is a rare condition characterized by the secretion of colored sweat. There are two types of glands such as apocrine and eccrine gland. Apocrine glands secrete a milky sweat that, once fragmented down by bacteria, is the main cause of body odor whereas Eccrine glands secrete an odorless…